|
|
|
|
| LEADER |
01502nam a2200301 u 4500 |
| 001 |
EB001840103 |
| 003 |
EBX01000000000000001004092 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Eltrombopag olamine (Revolade)
|h Elektronische Ressource
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2015, 2015
|
| 300 |
|
|
|a 1 PDF file
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Hepatitis C, Chronic
|
| 653 |
|
|
|a Pyrazoles / therapeutic use
|
| 653 |
|
|
|a Hydrazines / therapeutic use
|
| 653 |
|
|
|a Thrombocytopenia / drug therapy
|
| 653 |
|
|
|a Benzoates / therapeutic use
|
| 653 |
|
|
|a Drug Therapy, Combination
|
| 653 |
|
|
|a Treatment Outcome
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK362529
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this review was to perform a systematic review to evaluate the beneficial and harmful effects of eltrombopag 25 mg and 50 mg tablets used in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) to increase platelet counts in patients with thrombocytopenia (TCP) and chronic hepatitis C virus (HCV) infection to allow the initiation and maintenance of IFN-based therapy
|